Altis Labs leverages AI to accelerate clinical development and bring life-saving treatments to patients faster. They've built the industry's largest multi-modal oncology database to train proprietary models that accurately predict overall survival, addressing the limitations of current clinical trial endpoints. Their technology empowers biopharma companies to optimize trial design, prioritize effective drugs, and accelerate commercialization, with validated results in multiple Phase 3 lung cancer trials and partnerships with major pharmaceutical companies already in place.
What is the problem?
Clinical trial timelines and failure rates are the rate-limiting factors to develop a new drug. To anticipate efficacy and inform R&D decision making, every oncology trial today relies on overall response rate (ORR) and progression-free survival (PFS), which are weak surrogates for overall survival (FDA’s gold standard endpoint). As a result, biopharma (a) waste $90B+ per year on trials that ultimately fail to show OS benefit, and (b) might accidentally terminate blockbuster drugs.
What is their solution?
We built the industry’s largest multi-modal oncology database—over 210 million images and 300,000+ patient years of linked clinical data—to train our proprietary models that predict overall survival. Our models empower sponsors to prioritize development of their most efficacious drugs, optimize trial design, and accelerate commercialization.
